BridgeMD
Aspirin to prevent cardiovascular events in patients with pneumonia or influenza
EU CTIS ID: 2023-504553-12-01
What this study is testing
To investigate whether adding aspirin to standard therapy in patients with moderate to severe community-acquired pneumonia or influenza will reduce the incidence of acute coronary syndrome in hospitalized patients
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 40 years or older
- Any of the following respiratory infections: moderate to severe community-acquired pneumonia (defined as clinical signs of pneumonia, radiological evidence of a new infiltrate consistent with pneumonia, and severity score CURB-65 score ≥2 or PSI score ≥3) or influenza (defined as clinical signs of a respiratory infection and a positive influenza PCR test result).
- Admitted to hospital
You likely can't join if
- Conditions which require antiplatelet therapy
- Use of vitamin K antagonists, direct oral anticoagulants or therapeutic LMWH
- Contraindications for aspirin: recent (<1 month) hemorrhagic CVA, recent major gastro-intestinal bleeding or other hemorrhage, active bleeding, thrombocytopenia < 100, known hemorrhagic diathesis, allergy for salicylates.
- Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP>110 mm Hg)
- Life expectancy less than one month
- Pregnancy or breastfeeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.